Indegene
Market cap ₹15,773 Cr
- P/E
- 38.53
- Day range
- ₹646.05 – ₹662.55
- 52-week range
- ₹414.00 – ₹677.00
- Volume
- 3.13 L
- Open
- ₹647.85
- Prev close
- ₹648.75
Latest results · Q2 FY27(consolidated)Revenue ₹1,122 Cr+39.6%Profit ₹112 Cr+10.0%Margin 10.0%YoY vs the same quarter last year
1 red flag to read up on
- medium
Material exchange filing
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer · 29 Oct 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
INDGN in NSE indices and F&O
Research profile
Composite 66 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.6%
- Graham no.
- ₹233.40
- vs Graham
- -64.4%
- ROE ÷ P/B
- 2.9%
- 12-1 mom.
- +15.4%
- Return / vol
- 0.93
- Magic Formula
- #304
- Piotroski
- 1/6
- FCF yield
- 3.8%
Appears in 12 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| IndegeneINDGN | ₹15,773 Cr | 38.53 | 4.79 | 13.9% | 19.0% | 17.0% | 0.05 | +39.6% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 21h agoHeadlines about Indegene from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 37.0
- Price / Book
- 4.71
- ROE (FY26)
- 13.9%
- ROCE (latest year)
- 19%
- Dividend yield
- 0.34%
Moving averages (NSE)
- 20-day
- ₹616.14
- Price above
- 50-day
- ₹601.86
- Price above
- 200-day
- ₹530.59
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 673 | 673 | 676 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 | 1,122 |
| Expenses | 524 | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 | 937 |
| Operating Profit | 149 | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 | 186 |
| OPM % | 22% | 21% | 19% | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% | 17% |
| Other Income | 13 | 26 | 22 | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 | 15 |
| Interest | 12 | 12 | 12 | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 | 7 |
| Depreciation | 18 | 18 | 20 | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 | 46 |
| Profit before tax | 132 | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 | 147 |
| Tax % | 25% | 29% | 27% | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% | 24% |
| Net Profit | 99 | 95 | 88 | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 | 112 |
| EPS in Rs | ₹4.44 | ₹4.26 | ₹3.67 | ₹3.83 | ₹4.58 | ₹4.90 | ₹4.85 | ₹4.25 | ₹4.28 | ₹3.31 | ₹4.82 | ₹4.66 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-6 days since Mar 2021
-6 days since Mar 2021
-40 days since Mar 2021
Strengths, risks & growth
Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations [1]
Strengths
- Company is almost debt free.
- Company is expected to give good quarter
Risks
None flagged by the checklist.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +29%
- 3 Years
- +15%
- TTM
- +36%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +23%
- 3 Years
- +16%
- TTM
- -4%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +27%
Return on Equity
- 10 Years
- —
- 5 Years
- +21%
- 3 Years
- +19%
- Last Year
- +14%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| FII | 11.48% | 10.27% | 9.92% | 12.40% | +2.48 pp |
| DII | 8.06% | 8.29% | 8.74% | 15.82% | +7.08 pp |
| Public | 80.44% | 81.43% | 81.34% | 71.76% | -9.58 pp |
Filed with NSE for Sept 2026: promoters 0.00%, public 100.00%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 12.25% (+6.97 pp)- Promoters0.0%
- Foreign institutions12.4%
- Mutual funds12.3%
- Insurance0.1%
- Other domestic institutions3.5%
- Retail7.6%
- Others64.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Quant Small Cap Fund | 3.35% | 1.58% | +1.58 pp |
| ICICI Pru Small Cap Fund | 0.73% | 1.20% | +0.68 pp |
| ICICI Pru Healthcare Fund | 0.70% | 1.56% | +1.56 pp |
| Sundaram Mid Cap Fund | 0.58% | 0.68% | +0.13 pp |
| ICICI Pru Technology Fund | 0.57% | 0.70% | -0.01 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 28.2%
- Downside volatility
- 23.9%
- Worst 5% of days
- 2.6%
- Average of that tail
- 3.3%
- Max drawdown (1Y)
- 27.8%
- Below its peak
- 1.7%
Against the market
- Beta vs Nifty 50
- 0.70
- Correlation
- 0.34
- Relative strength (3M)
- +12.7%
- ATR (14)
- 3.3%
Return
- Return 1M
- +9.5%
- Return 3M
- +16.6%
- Return 6M
- +28.4%
- Return 1Y
- +26.4%
- vs 200-day average
- +23.4%
Momentum
- RSI (14)
- 64.5
- MACD histogram
- 4.90
- Stochastic %K
- 78.0
- ADX (14)
- 24.7
- +DI / −DI
- 28.0 / 13.6
- Money flow index
- 74.0
Participation
- Delivery (20d avg)
- 61.7%
- vs its 60-day baseline
- +5.6 pts
- Volume vs 20-day
- -0.6σ
- Close vs day's VWAP
- +0.0%
- 52-week position
- 95 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
1 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹606 Cr
- FCF yield
- 3.8%
- Cash conversion
- 1.62
- Accruals ratio
- -0.054
- Net debt
- ₹16 Cr
- Net debt / equity
- 0.00
- EV / sales
- 3.82
- Capex intensity
- 1.3%
- Revenue CAGR
- 30.1%
- Profit CAGR
- -3.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Anita Nair Immediate relative · Market Purchase | Buy | 22,230 | ₹100.0 L | 24 Mar 2026 |
Sameer Narendrakumar Lal Other · Market Sale | Sell | 60,000 | ₹2.9 Cr | 4 Mar 2026 |
Sameer Narendra Lal Market Sale | Sell | 10,000 | ₹51.3 L | 18 Nov 2025 |
BINA PATIL Market Sale | Sell | 2,000 | ₹10.3 L | 14 Nov 2025 |
BINA PATIL Market Sale | Sell | 5,930 | ₹31.1 L | 14 Nov 2025 |
BINA PATIL Market Sale | Sell | 500 | ₹2.6 L | 14 Nov 2025 |
BINA PATIL Market Sale | Sell | 13,570 | ₹69.8 L | 14 Nov 2025 |
AMIT GUPTA | Sell | 2,200 | ₹11.4 L | 14 Nov 2025 |
AMIT GUPTA | Sell | 2,200 | ₹11.4 L | 14 Nov 2025 |
AMIT GUPTA | Sell | 2,200 | ₹11.4 L | 14 Nov 2025 |
BINA SANJEEV PATIL Market Sale | Sell | 5,930 | ₹31.1 L | 13 Nov 2025 |
BINA SANJEEV PATIL Market Sale | Sell | 500 | ₹2.6 L | 13 Nov 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹2.25
Dividend - Rs 2.25 Per Share
31 Jul 2026ex-date - dividend₹2.00
Dividend - Rs 2 Per Share
13 Jun 2025ex-date - otherNot available — not reported in this filing
Annual General Meeting
29 Aug 2024ex-date
Company announcements
Intimation of Investors / Analysts Meeting
Transcript of the Q2 FY27 Earnings Call
Intimation of Newspaper Publication
Audio Recording of the Q2 FY27 Earnings Call
Audio Recording of the Q2 FY27 Earnings Call
Analyst Presentation and Fact Sheet - financial results for the 2nd quarter and half year ended 30th September, 2026
Press Release
Intimation of Resignation of Ms. Srishti Ramesh Kaushik (M. No A21609) from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company.
Allotment of shares under RSU Scheme 2020 and ESOP Scheme 2020
Unaudited Financial Results for the 2nd quarter and half year ended 30th September 2026
Outcome of the Board Meeting
Acquisition
Press Release
Resignation of Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive Non Independent Director of the Company
Certificate under Regulation 74 (5) of SEBI DP Regulations, 2018
Filed with BSE (scrip 544172); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026Slides
- May 2026TranscriptSlidesRecording
- Apr 2026Slides
- Feb 2026TranscriptSlidesRecording
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Indegene: common questions
Answered from the figures on this page.